Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058

Status:
Recruiting

Trial end date:
2022-11-01

Target enrollment:

Participant gender:

This is a study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of FTX-6058 in subjects with sickle cell disease.

Phase 1

Fulcrum Therapeutics